BICO Group AB (CHIX:BICOS) Risk Assessment


CHIX:BICOS BICO Group AB CHIX:BICOS
64 GF Score
Price kr45.75
GF Value kr84.36
! 4 Warning Signs
View Full Analysis

What is BICO Group AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BICO Group AB is: No Data: Cannot be evaluated.

BICO Group AB  (CHIX:BICOs) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BICO Group AB Risk Assessment Related Terms

CHIX:BICOS vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, BICO Group AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BICO Group AB Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BICO Group AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BICO Group AB's Risk Assessment falls into.


CHIX:BICOS
64GF Score
BICO Group AB CHIX:BICOS
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BICO Group AB (CHIX:BICOS) Overvalued in 2026?

Based on GuruFocus' analysis, BICO Group AB stock appears to be undervalued. The current stock price of kr45.75 is trading 45.8% below its estimated GF Value™ of kr84.36.

Key valuation signals for CHIX:BICOS:

  • Risk Assessment:
  • GF Value™: kr84.36 vs. price of kr45.75 (45.8% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BICOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BICO Group AB Business Description

Address Grafiska vagen 2B, Gothenburg, SWE, 412 63
BICO Group AB provides hardware, laboratory automation software, and products to automate and increase efficiency in workflows for pharma and biotech companies. Its portfolio includes automated workstations, lab automation software, microscopes and live-cell imaging, 3D cell culture and bioprinting, single-cell dispensing, liquid handling, mixing technologies, and consumables. The Group operates through two segments: Life Science Solutions, the maximum revenue generator, including CYTENA, DISPENDIX, Discover Echo, QInstruments, SCIENION, Cellenion, CELLINK, and BioMatrix, and Lab Automation, consisting of Biosero, which provides the Green Button Go Suite software and automation integration services.
64GF Score

Get the complete analysis for CHIX:BICOS

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr45.75
Price
kr84.36
GF Value